



# Redsense releases Aktiespararna CEO interview following Q4 2025 report

Halmstad, Sweden, February 19, 2026 – Redsense Medical AB (publ) (“Redsense” or “the Company”) announces that a video interview with CEO Sebastien Bollue has been published by Aktiespararna.

In the interview, Sebastien Bollue comments on the recently released Q4 2025 report, reflects on the past year, and provides priorities for 2026.

The interview is available on the Aktiespararna website: <http://www.aktiespararna.se/analyser/vd-intervju-redsense-medical>

It is also accessible via the following link: <http://www.youtube.com/watch?v=YEQI1QQTYg8>

## Contact information

For more information, please contact:  
Sebastien Bollue, CEO  
Telephone: +46 72-171 1264  
E-mail: [sebastien.bollue \(at\) redsensemical.com](mailto:sebastien.bollue@redsensemical.com)

Redsense Medical AB (publ), 556646-4862

## ABOUT REDSENSE MEDICAL

Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovation used for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector. The Redsense Medical share is listed on Spotlight Stock Market (REDS)